Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28477707 | 0.83 | DRD2 (0.36) | S1PR1S1PR3S1PR5DRD2HRH3 | |
| SCHEMBL3298160 | 0.79 | S1PR1 (0.38) | S1PR1S1PR3S1PR5DRD2HRH3 | |
| SCHEMBL28366130 | 0.79 | S1PR1 (0.38) | S1PR1S1PR3S1PR5DRD2HRH3 | |
| SCHEMBL21246968 | 0.79 | NOS3 (0.32) | S1PR1S1PR3S1PR5HRH3 | |
| SCHEMBL25698068 | 0.78 | DRD2 (0.36) | DRD2 | |
| SCHEMBL22096471 | 0.78 | S1PR1 (0.60) | S1PR1S1PR3S1PR5S1PR4SIGMAR1 | |
| SCHEMBL19606301 | 0.78 | S1PR1 (0.60) | S1PR1S1PR3S1PR5S1PR4SIGMAR1 | |
| SCHEMBL22096478 | 0.78 | S1PR1 (0.60) | S1PR1S1PR3S1PR5S1PR4SIGMAR1 | |
| SCHEMBL24134155 | 0.76 | CARM1 (0.42) | S1PR1S1PR3S1PR5DRD2HRH3 | |
| SCHEMBL21792822 | 0.76 | GBA1 (0.40) | S1PR1S1PR3S1PR5DRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3750893-B1 | DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-11407760-B2 | Dioxinoquinoline compounds, preparation method and uses thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-08-09 | — | — | US | disclosed |
| CN-111788207-B | Dioxane quinoline compound and preparation method and application thereof | 北京赛特明强医药科技有限公司 | 2021-03-23 | — | — | CN | disclosed |
| US-20200399285-A1 | DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF | ACCSALUS BIOSCIENCES LIMITED (VG) | 2020-12-24 | — | — | US | disclosed |
| EP-3750893-A1 | DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2020-12-16 | — | — | EP | disclosed |
| CN-111788207-A | Dioxane quinoline compound and preparation method and application thereof | 北京赛特明强医药科技有限公司 | 2020-10-16 | — | — | CN | disclosed |
| WO-2019154133-A1 | DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | 北京赛特明强医药科技有限公司 | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407760-B2 | Dioxinoquinoline compounds, preparation method and uses thereof | KDR, MET, ABL1 | S1PR1 1316/4885S1PR3 1249/4885S1PR5 1041/4885 |
| US-20200399285-A1 | DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF | KDR, MET, ABL1 | S1PR1 1316/4885S1PR3 1249/4885S1PR5 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.